HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (32) Citing Articles via Google Scholar Google Scholar Articles by Imhof, A. Articles by Koenig, W. Search for Related Content PubMed PubMed Citation Articles by Imhof, A. Articles by Koenig, W. Related Collections General Clinical Chemistry Lipids, Lipoproteins, and Cardiovascular Risk Factors

Distributions of C-reactive Protein Measured by High-Sensitivity Assays in Apparently Healthy Men and Women from Different Populations in Europe

¹ Department of Internal Medicine II, Cardiology, University of Ulm, D-89081 Ulm, Germany

² GSF-National Research Center for Environment and Health, Institute for Epidemiology, 85764 Neuherberg, Germany

³ Inserm U508, Institut Pasteur de Lille, 59079 Lille Cedex, France

⁴ Institute for International Health, University of Sydney, Sydney NSW 2042, Australia

⁵ Department of Medicine, Royal Infirmary, Glasgow G31 2ER, United Kingdom

^aaddress correspondence to this author at: Department of Internal Medicine II, Cardiology University of Ulm, Robert-Koch-Strasse 8, D-89081 Ulm, Germany; fax 49-731-500-33872, e-mail wolfgang.koenig@medizin.uni-ulm.de

The first 300 words of the full text of this article appear below.

C-reactive protein (CRP), the classic marker of acute-phase response, is an indicator of a variety of pathologic processes, including infections, tissue damage, and chronic inflammatory diseases (1)(2). The majority of more than 15 well-conducted prospective studies in initially healthy individuals have shown a strong and independent association between concentrations of CRP within the reference interval (<5 mg/L) and future major cardiovascular events (3), although in some of them, no such association could be established (4)(5)(6)(7). The summary estimate of the relative risk in formal metaanalysis was 2.0 (95% confidence interval, 1.6–2.5) (3). Furthermore, CRP has been shown to add to risk prediction beyond and above established cardiovascular risk factors (8). On the basis of data from the Physicians’ Health Study and the Nurses’ Health Study, an algorithm for risk assessment of future coronary events that combines both CRP concentration and the ratio of total cholesterol to HDL-cholesterol has recently been proposed (9).

Because atherosclerosis represents a low-grade inflammatory process in the vascular bed, high-sensitivity (hs) assays are needed when using circulating CRP concentrations for risk prediction in cardiovascular diseases. Such assays have been developed and are now commercially available (10)(11). However, before screening of individuals at risk can be recommended, CRP distributions in apparently healthy adults in the general population must be known. Such information is scarce. Furthermore, in previous reports, women using oral contraceptives or receiving hormone replacement therapy (HRT), both of which have been shown to significantly increase CRP concentrations, had not been excluded (12)(13)(14)(15). In this report, we describe the frequency distribution of CRP concentrations in 13 527 adult men and women from different representative . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				C. P. Hersh, D. T. Miller, D. J. Kwiatkowski, and E. K. Silverman Genetic determinants of C-reactive protein in COPD Eur. Respir. J., December 1, 2006; 28(6): 1156 - 1162. [Abstract] [Full Text] [PDF]

				P. C. Kao, S.-C. Shiesh, and T.-J. Wu Serum C-reactive protein as a marker for wellness assessment. Ann. Clin. Lab. Sci., March 1, 2006; 36(2): 163 - 169. [Abstract] [Full Text] [PDF]

				K. S Kornman Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging Am. J. Clinical Nutrition, February 1, 2006; 83(2): 475S - 483S. [Abstract] [Full Text] [PDF]

				B. Dasch, A. Fuhs, T. Behrens, A. Meister, J. Wellmann, M. Fobker, D. Pauleikhoff, and H.-W. Hense Inflammatory Markers in Age-Related Maculopathy: Cross-sectional Analysis From the Muenster Aging and Retina Study Arch Ophthalmol, November 1, 2005; 123(11): 1501 - 1506. [Abstract] [Full Text] [PDF]

				A. Stefanska, G. Sypniewskay, and L. Senterkiewicz Inflammatory Markers and Cardiovascular Risk in Healthy Polish Women across the Menopausal Transition Clin. Chem., October 1, 2005; 51(10): 1893 - 1895. [Full Text] [PDF]

				D. E. Laaksonen, L. Niskanen, K. Nyyssonen, K. Punnonen, T.-P. Tuomainen, and J. T. Salonen C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study Eur. Heart J., September 1, 2005; 26(17): 1783 - 1789. [Abstract] [Full Text] [PDF]

				A. Khera, D. K. McGuire, S. A. Murphy, H. G. Stanek, S. R. Das, W. Vongpatanasin, F. H. Wians Jr, S. M. Grundy, and J. A. de Lemos Race and Gender Differences in C-Reactive Protein Levels J. Am. Coll. Cardiol., August 2, 2005; 46(3): 464 - 469. [Abstract] [Full Text] [PDF]

				M. Di Napoli, M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H. C.A. Emsley, S. Forconi, S. J. Hopkins, L. Masotti, et al. Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke: A Statement for Health Care Professionals From the CRP Pooling Project Members Stroke, June 1, 2005; 36(6): 1316 - 1329. [Abstract] [Full Text] [PDF]

				G. L. Myers, N. Rifai, R. P. Tracy, W. L. Roberts, R. W. Alexander, L. M. Biasucci, J. D. Catravas, T. G. Cole, G. R. Cooper, B. V. Khan, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Report From the Laboratory Science Discussion Group Circulation, December 21, 2004; 110(25): e545 - e549. [Full Text] [PDF]

				M. Lambert, E. E. Delvin, G. Paradis, J. O'Loughlin, J. A. Hanley, and E. Levy C-Reactive Protein and Features of the Metabolic Syndrome in a Population-Based Sample of Children and Adolescents Clin. Chem., October 1, 2004; 50(10): 1762 - 1768. [Abstract] [Full Text] [PDF]

				V. Tsimihodimos, A. Kostoula, A. Kakafika, E. Bairaktari, A. D. Tselepis, D. P. Mikhailidis, and M. Elisaf Effect of Fenofibrate on Serum Inflammatory Markers in Patients With High Triglyceride Values Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1): 27 - 33. [Abstract] [PDF]

				E. S. Ford, W. H. Giles, A. H. Mokdad, and G. L. Myers Distribution and Correlates of C-Reactive Protein Concentrations among Adult US Women Clin. Chem., March 1, 2004; 50(3): 574 - 581. [Abstract] [Full Text] [PDF]

				A. J. MacGregor, J. R. Gallimore, T. D. Spector, and M. B. Pepys Genetic Effects on Baseline Values of C-Reactive Protein and Serum Amyloid A Protein: A Comparison of Monozygotic and Dizygotic Twins Clin. Chem., January 1, 2004; 50(1): 130 - 134. [Abstract] [Full Text] [PDF]

				N. Khuseyinova, A. Imhof, G. Trischler, D. Rothenbacher, W. L. Hutchinson, M. B. Pepys, and W. Koenig Determination of C-Reactive Protein: Comparison of Three High-Sensitivity Immunoassays Clin. Chem., October 1, 2003; 49(10): 1691 - 1695. [Full Text] [PDF]

				T. B. Ledue and N. Rifai Preanalytic and Analytic Sources of Variations in C-reactive Protein Measurement: Implications for Cardiovascular Disease Risk Assessment Clin. Chem., August 1, 2003; 49(8): 1258 - 1271. [Abstract] [Full Text] [PDF]